Search
Ambrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalAmbrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve e...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: AMBRISENTAN DR. REDDY?SRetifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigationaldeath-ligand 2 (PD-L2). … Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsSynonyms: Anti-PD-1 monoclonal antibody MGA012Relatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41305] As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic
Cinacalcet
go.drugbank.com/drugs/DB01012ApprovedInvestigationalIt is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: CINACALCET DR. REDDY'SAluminum chlorohydrate
go.drugbank.com/drugs/DB11573ApprovedAluminum chlorohydrate is a group of water-soluble aluminum complexes with the general formula AlnCl(3n-m)(OH)m. It is included up to 25% in over-the-counter hygiene products as an active antiperspirant agent. The primary site of action ...
Products: Jardins Du Monde Antisudorifique A Bille, Jardins du Monde Indian Cotton Flower Antiperspirant Roll-OnSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalSunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant g...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: SUNITINIB DR. REDDY'SMorphine
go.drugbank.com/drugs/DB00295ApprovedInvestigational[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: Astramorph PFKetoconazole
go.drugbank.com/drugs/DB01026ApprovedInvestigational[A188054] At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption.
Mixtures: SPORUM-D, TREXEN DUOCategories: P-glycoprotein inhibitors, P-glycoprotein substratesCarboplatin
go.drugbank.com/drugs/DB00958ApprovedInvestigationalCarboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with ...
Products: Paraplatin Inj 150mg/vial, BLASTOCARB RU